Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Completed · Phase 1/Phase 2
Conditions studied: Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer
In brief
This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)
Key facts
- Study ID
- NCT02657889
- Run by
- Tesaro, Inc.
- People needed
- 122
- Starts
- 2016-04-15
- Expected to finish
- 2021-09-17
- Last updated by the study team
- 2022-12-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- GSK Investigational Site — Birmingham, Alabama, United States
- GSK Investigational Site — Phoenix, Arizona, United States
- GSK Investigational Site — Scottsdale, Arizona, United States
- GSK Investigational Site — Los Angeles, California, United States
- GSK Investigational Site — San Francisco, California, United States
- GSK Investigational Site — Stanford, California, United States
- GSK Investigational Site — Washington D.C., District of Columbia, United States
- GSK Investigational Site — Deerfield Beach, Florida, United States
- GSK Investigational Site — Jacksonville, Florida, United States
- GSK Investigational Site — Miami, Florida, United States
- GSK Investigational Site — Orlando, Florida, United States
- GSK Investigational Site — Chicago, Illinois, United States
- GSK Investigational Site — Covington, Louisiana, United States
- GSK Investigational Site — Boston, Massachusetts, United States
- GSK Investigational Site — Boston, Massachusetts, United States
- GSK Investigational Site — Boston, Massachusetts, United States
- GSK Investigational Site — Burlington, Massachusetts, United States
- GSK Investigational Site — Detroit, Michigan, United States
- GSK Investigational Site — Rochester, Minnesota, United States
- GSK Investigational Site — Morristown, New Jersey, United States
- GSK Investigational Site — New York, New York, United States
- GSK Investigational Site — Chapel Hill, North Carolina, United States
- GSK Investigational Site — Charlotte, North Carolina, United States
- GSK Investigational Site — Cleveland, Ohio, United States
- GSK Investigational Site — Oklahoma City, Oklahoma, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.